116 related articles for article (PubMed ID: 12873679)
21. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction
Aguilera MDV; Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Garcia-Migue J; Cortes S; Agusti E; Camacho C; Zhang Y; Li Y; Sabater S; Torne A; Arenas M
J Contemp Brachytherapy; 2018 Feb; 10(1):40-46. PubMed ID: 29619055
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the interfractional biological effective dose (BED) variation in MammoSite high dose rate brachytherapy.
Kim Y; Werts ED; Trombetta MG; Miften M
J Appl Clin Med Phys; 2010 Jun; 11(3):3228. PubMed ID: 20717092
[TBL] [Abstract][Full Text] [Related]
23. Postoperative brachytherapy and electron beam irradiation for keloids: A single institution retrospective analysis.
Duan Q; Liu J; Luo Z; Hu C
Mol Clin Oncol; 2015 May; 3(3):550-554. PubMed ID: 26137265
[TBL] [Abstract][Full Text] [Related]
24. Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya.
Maranga IO; Hampson L; Oliver AW; Gamal A; Gichangi P; Opiyo A; Holland CM; Hampson IN
PLoS One; 2013; 8(10):e78411. PubMed ID: 24205226
[TBL] [Abstract][Full Text] [Related]
25. Predictors of tumor response in carcinoma of uterine cervix: data from tertiary cancer centre in India.
Pathy S; Muwonge R; Chander S; Dadhwal V; Pandjatcharam J
Bull Cancer; 2014 Feb; 101(2):E13-8. PubMed ID: 24590357
[TBL] [Abstract][Full Text] [Related]
26. Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?
Zhang Y; Ascaso C; Herreros A; Sánchez J; Sabater S; Pino MD; Li Y; Gómez G; Torné A; Biete A; Rovirosa Á
Rep Pract Oncol Radiother; 2020; 25(2):227-232. PubMed ID: 32042274
[TBL] [Abstract][Full Text] [Related]
27. Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series.
Delishaj D; Laliscia C; Manfredi B; Ursino S; Pasqualetti F; Lombardo E; Perrone F; Morganti R; Paiar F; Fabrini MG
J Contemp Brachytherapy; 2015 Dec; 7(6):437-44. PubMed ID: 26816500
[TBL] [Abstract][Full Text] [Related]
28. Fletcher suit or ring: A comparison of Fletcher suit and ring applicators for retroverted uteri.
Rao V; Zade B; Singh S; Narayanan VKS; Moundekar P
J Contemp Brachytherapy; 2024 Apr; 16(2):128-131. PubMed ID: 38808206
[TBL] [Abstract][Full Text] [Related]
29. Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancer.
Kleinerman RA; Smith SA; Holowaty E; Hall P; Pukkala E; Vaalavirta L; Stovall M; Weathers R; Gilbert E; Aleman BM; Kaijser M; Andersson M; Storm H; Joensuu H; Lynch CF; Dores GM; Travis LB; Morton LM; Curtis RE
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):922-9. PubMed ID: 23707149
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a novel scoring system to predict the risk of uterine perforation during intracavitary brachytherapy for cervical cancer.
M Parvath ES; John NO; Sathyamurthy A; Ramireddy JK; Ram TS
J Gynecol Oncol; 2024 May; 35(3):e35. PubMed ID: 38178701
[TBL] [Abstract][Full Text] [Related]
31. Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy.
Laliscia C; Coccia N; Fuentes T; Perrone F; Paiar F
J Contemp Brachytherapy; 2021 Dec; 13(6):615-619. PubMed ID: 35079246
[TBL] [Abstract][Full Text] [Related]
32. Radiation Proctitis in Patients With Locally Advanced Cervical Cancer Treated by Chemoradiation: Analysis and Predictive Factors From a Retrospective Cohort.
Sauvage LM; Bentahila R; Tran Y; Guénégou-Arnoux A; Fabiano E; Bats AS; Borghese B; Durdux C
Am J Clin Oncol; 2024 Apr; ():. PubMed ID: 38557436
[TBL] [Abstract][Full Text] [Related]
33. Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes.
Tormo A; Celada F; Rodriguez S; Botella R; Ballesta A; Kasper M; Ouhib Z; Santos M; Perez-Calatayud J
J Contemp Brachytherapy; 2014 Jun; 6(2):167-72. PubMed ID: 25097557
[TBL] [Abstract][Full Text] [Related]
34. Communicating the Gynecologic Brachytherapy Experience (CoGBE): Clinician perceived benefits of a graphic narrative discussion guide.
Avila S; Ruiz MJ; Petereit D; Arya R; Callender B; Hasan Y; Kim J; Lee N; McCall A; Son C; Stack K; Asif S; Besecker T; Juneja A; Li Z; Naik P; Ranka T; Saxena P; Siegfried B; Ichikawa T; Golden DW
Brachytherapy; 2023; 22(3):352-360. PubMed ID: 36681540
[TBL] [Abstract][Full Text] [Related]
35. Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer
Sitler CA; Tian C; Hamilton CA; Richardson MT; Chan JK; Kapp DS; Leath CA; Casablanca Y; Washington C; Chappell NP; Klopp AH; Shriver CD; Tarney CM; Bateman NW; Conrads TP; Maxwell GL; Phippen NT; Darcy KM
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473428
[TBL] [Abstract][Full Text] [Related]
36. Irradiation-induced bone sarcoma in a patient treated for cervix cancer 28 years earlier.
Klimek M; Wilk W; Szostek S; Luczyńska E; Bieda T; Kojs Z; Ryś J
Contemp Oncol (Pozn); 2012; 16(1):56-9. PubMed ID: 23788856
[TBL] [Abstract][Full Text] [Related]
37. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation.
Orton CG; Seyedsadr M; Somnay A
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1425-34. PubMed ID: 1938550
[TBL] [Abstract][Full Text] [Related]
38. Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy.
Zhong Q; Tang F; Ni T; Chen Y; Liu Y; Wu J; Zhou W; Feng Z; Lu X; Tan S; Zhang Y
Front Immunol; 2022; 13():995930. PubMed ID: 36325337
[TBL] [Abstract][Full Text] [Related]
39. Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer.
Mukai Y; Minagawa Y; Inoue H; Sato A; Matsui K; Fukuda T; Onuma K; Hongo H; Shirata R; Nagata H; Hashimoto H; Inoue T; Hata M; Omura M
In Vivo; 2020; 34(6):3387-3398. PubMed ID: 33144446
[TBL] [Abstract][Full Text] [Related]
40. Effects of an alpha-1d adrenoreceptor antagonist (naftopidil) on bladder dysfunction after radiotherapy in female rats.
Lee SJ; Kim HY; Lee DS
Int Urogynecol J; 2021 Oct; 32(10):2747-2755. PubMed ID: 32761376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
